PureTech Health Revenue and Competitors
Estimated Revenue & Valuation
- PureTech Health's estimated annual revenue is currently $28.3M per year.
- PureTech Health received $50.0M in venture funding in January 2015.
- PureTech Health's estimated revenue per employee is $193,750
- PureTech Health's total funding is $14.7M.
Employee Data
- PureTech Health has 146 Employees.
- PureTech Health grew their employee count by -5% last year.
PureTech Health's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Clinical Pharmacology | Reveal Email/Phone |
2 | Head Quality Assurance | Reveal Email/Phone |
3 | SVP, Human Resources | Reveal Email/Phone |
4 | Head Innovation | Reveal Email/Phone |
5 | VP Research | Reveal Email/Phone |
6 | VP Clinical Development - Respiratory | Reveal Email/Phone |
7 | Director Accounting and Financial Reporting | Reveal Email/Phone |
8 | Director Clinical Operations | Reveal Email/Phone |
9 | Senior Director Clinical Operations | Reveal Email/Phone |
10 | Associate Director, IP Strategy | Reveal Email/Phone |
PureTech Health Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is PureTech Health?
PureTech Health (LSE: PRTC) is an advanced, clinical-stage biopharmaceutical company developing novel medicines around the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insight into the connection between these systems and the resulting role in many chronic diseases, which represent the majority of healthcare spend and have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health has developed new categories of medicines with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies across two divisions. Its Affiliates division includes two product candidates that are preparing for potential regulatory approval in the United States and Europe and a number of clinical and pre-clinical programmes. These affiliates have developed ground-breaking platforms and therapeutic candidates in collaboration with some of the world's leading scientific experts. PureTech's Internal division is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programmes build on a new understanding of the trafficking and biodistribution of various immune system components in order to develop targeted therapies for diseases with major unmet needs including cancer and autoimmune and neuroimmune disorders. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$14.7M
Total Funding
146
Number of Employees
$28.3M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PureTech Health News
The image below, which you can click on for greater detail, shows that PureTech Health had debt of US$19.0m at the end of December 2021, a...
PureTech Health PLC reported a swing to pretax loss in 2021 on higher costs. The biotechnology company said pretax loss was of 59.0 million...
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics...
PureTech Health plc PureTech Receives Approximately $100 Million from Sale of a Portion of Founded Entity Shares PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, today announces that it has sold 750,000 shares of its Founded ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vedanta Biosciences (“Vedanta”) today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.3M | 146 | -3% | N/A |
#2 | $7.5M | 146 | 33% | N/A |
#3 | $33.7M | 146 | -36% | N/A |
#4 | $43.4M | 146 | -1% | N/A |
#5 | N/A | 146 | 8% | N/A |
PureTech Health Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-10-21 | $55.0M | Undisclosed | Invesco Perpetual | Article |
| 2015-01-12 | $50.0M | Undisclosed | Article |